semaglutide category Effects of Once-Weekly on Kidney Disease Outcomes by KDIGO Risk in the SUSTAIN 6 Trial what are the brand names

It's a great way to differentiate in a crowded market

Discussion This observational cohort study describes real-world utilization patterns and characteristics of patients dispensed an SGLT2i or GLP-1 RA in the US using data from Optum CDM in the period following changes to the landscape for treatment and prevention of CKD in type 2 diabetes (later period, July 2021September 2023) as well as temporal changes in utilization and baseline characteristics relative to the period prior (earlier period, January 2012June 2021)

Published large human clinical-trial data is not available, so a regulator-grade answer to that question does not exist

The fix: A knowledgeable GI provider can help determine the causes of your symptoms